InMed Provides Update on Management Changes
November 17 2022 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:
INM), a leader in the pharmaceutical research, development and
manufacturing of rare cannabinoids and cannabinoid analogs, today
announces that Sarah Li has been promoted to Vice President of
Accounting and Controller at InMed. Ms. Brenda Edwards will be
transitioning out of her position as interim Chief Financial
Officer at the Company effective November 20, 2022. Ms.
Edwards joined the Company in an interim contract role to assist
the Company with financial reporting matters following the
retirement of the Company’s former Chief Financial Officer in March
2022.
The Company is currently in discussions to
finalize the engagement of interim financial leadership consulting
services.
“We are pleased to announce this promotion of
Ms. Li to her new position as VP of Accounting and Controller. She
is a valued employee who has grown in her responsibilities and
overall contribution level to the Company over the past several
years,” commented Eric A. Adams, InMed President and Chief
Executive Officer. “Also, on behalf of the Board of Directors and
our employees, I would like to thank Ms. Edwards for her hard work
as interim CFO of InMed and we wish her all the best in her future
endeavors.”
About InMed: InMed
Pharmaceuticals is a global leader in the pharmaceutical research,
development and manufacturing of rare cannabinoids and cannabinoid
analogs, including clinical and preclinical programs targeting the
treatment of diseases with high unmet medical needs. We also have
significant know-how in developing proprietary manufacturing
approaches to produce cannabinoids for various market sectors. For
more information, visit www.inmedpharma.com and
www.baymedica.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about; being a global leader in the
pharmaceutical research, development and manufacturing of rare
cannabinoids and cannabinoid analogs; InMed’s position within the
pharmaceutical research market; the effective date of Ms. Edwards
resignation; and about discussions to finalize the engagement of
interim financial leadership consulting services.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024